Reaction Biology Corp. (RBC) has signed an agreement with Cisbio Bioassays, a biotechnology company that provides services for human in vitro diagnostics and pharmaceutical research, to distribute its epigenetic proteins. RBC manufactures recombinant human epigenetic proteins that modulate genetic function in humans and are being researched as targets for next generation cancer drugs. Cisbio develops and markets assays for drug discovery research and has recently expanded its product offering with solutions to assess epigenetic targets such as methyltransferases. Cisbio will have worldwide rights to co-market and sell RBC’s proteins.
 
“RBC’s portfolio of epigenetic proteins is projected to grow to over 200 this year,” said Dr. Haiching Ma, RBC chief scientific officer. “With more and more international interest, we felt a relationship with an outstanding distributor like Cisbio would bring these proteins to the widest possible client base.”
 
“We have been seeing increasing demand for high quality epigenetic proteins that can be included in the assays that we currently develop,” said Patrick Seguin, vice president of sales and marketing. “RBC’s proteins have met all of our requirements for purity and activity levels, and this agreement represents one step forward in our goal to become a premier provider of epigenetic assays.”